SCHEMBL1565403

SCHEMBL1565403

CCCCC(Oc1ccc(F)c(F)c1)C(=O)Nc1nccs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.50
▸ HSPA5 P11021 2/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ FFAR2 O15552 2/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ CDK5 Q00535 1/20 0.45
▸ CDK5R1 Q15078 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1564907 0.89 TP53 (0.55) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1565628 0.86 TP53 (0.54) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1565298 0.86 NPC1 (0.56) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1565765 0.85 LMNA (0.53) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1566200 0.85 NPC1 (0.58) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1565038 0.84 RAB9A (0.54) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1565317 0.84 LMNA (0.56) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1565548 0.84 HSPA5 (0.49) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1566465 0.83 CYP1A2 (0.55) LMNAHSPA5L3MBTL1FFAR2CYP1A2
SCHEMBL1565655 0.83 HSPA5 (0.52) LMNAHSPA5L3MBTL1FFAR2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US claimed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP claimed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-1458382-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US disclosed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171411-A1 Amide derivatives as therapeutic agents GK, GCKR, GCK LMNA 3743/4885HSPA5 3181/4885L3MBTL1 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback